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Abstract
Amylin reduces meal size by activating noradrenergic neurons in the area postrema (AP). Neurons in the AP also mediate the
eating-inhibitory effects of salmon calcitonin (sCT), a potent amylin agonist, but the phenotypes of the neurons mediating its effect
are unknown. Here we investigated whether sCT activates similar neuronal populations to amylin, and if its anorectic properties
also depend on AP function. Male rats underwent AP lesion (APX) or sham surgery. Meal patterns were analysed under ad
libitum and post-deprivation conditions. The importance of the AP in mediating the anorectic action of sCT was examined in feed-
ing experiments of dose–response effects of sCT in APX vs. sham rats. The effect of sCT to induce Fos expression was com-
pared between surgery groups, and relative to amylin. The phenotype of Fos-expressing neurons in the brainstem was examined
by testing for the co-expression of dopamine beta hydroxylase (DBH) or tryptophan hydroxylase (TPH). By measuring the apposi-
tion of vesicular glutamate transporter-2 (VGLUT2)-positive boutons, potential glutamatergic input to amylin- and sCT-activated
AP neurons was compared. Similar to amylin, an intact AP was necessary for sCT to reduce eating. Further, co-expression
between Fos activation and DBH after amylin or sCT did not differ markedly, while co-localization of Fos and TPH was minor.
Approximately 95% of neurons expressing Fos and DBH after amylin or sCT treatment were closely apposed to VGLUT2-positive
boutons. Our study suggests that the hindbrain pathways engaged by amylin and sCT share many similarities, including the
mediation by AP neurons.
Introduction
Amylin and calcitonin are structurally and functionally related pep-
tides of the calcitonin-like gene peptide superfamily (Wimalawansa,
1997). Amylin and calcitonin share a common core receptor, the
calcitonin receptor (CTR), which is transformed into a speciﬁc amy-
lin receptor by receptor activity-modifying proteins (RAMPs; Sexton
et al., 1994; Christopoulos et al., 1999; Muff et al., 1999), speciﬁ-
cally RAMP1 and RAMP3. Amylin is co-secreted with insulin from
pancreatic b-cells (Butler et al., 1990; Ogawa et al., 1990), and one
physiological response that amylin and calcitonin share is the inhibi-
tion of eating (Lutz et al., 2000). While the anorectic action of
mammalian calcitonin is relatively weak, ﬁsh-derived calcitonin, like
salmon calcitonin (sCT), has often been used in pharmacological
studies aimed at identifying the mechanism of action of amylin
(Lutz et al., 2000). In contrast to amylin, sCT displays stronger,
irreversible receptor binding, which translates into a more potent,
longer-lasting eating-inhibitory response (Riediger et al., 1999; Lutz
et al., 2000; Reidelberger et al., 2002).
Strong evidence suggests that the area postrema (AP) is an impor-
tant brain site mediating amylin’s anorectic effect (Lutz, 2012).
Lesions of the AP and its amylin receptor population abolish periph-
eral amylin’s eating-inhibitory effects (Lutz et al., 1998, 2001; Mack
et al., 2010). Administration of exogenous peripheral amylin induces
a strong Fos response in the AP and in several downstream nuclei,
including the nucleus of the solitary tract (NTS; Rowland et al.,
1997; Rowland & Richmond, 1999; Barth et al., 2004; Riediger
et al., 2004). The neurochemical phenotypes of the neurons mediat-
ing the inhibitory effects of amylin and sCT on eating are only
partially identiﬁed. Approximately 50% of amylin-activated cells
expressing Fos protein within the AP were also positive for the spe-
ciﬁc noradrenergic marker, dopamine beta hydroxylase (DBH; Potes
et al., 2010b). These DBH-positive neurons seem to be functionally
relevant, because ablating them with saporin toxin reduced the ano-
rectic action of amylin (Potes et al., 2010b). It is unknown which
neuronal populations are speciﬁcally activated by sCT, and whether
sCT also activates the same noradrenergic population as amylin.
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More generally, ablating the AP not only prevents the anorectic
effect of amylin, but also alters physiological feedback mechanisms
that lead to a disruption in meal patterns (Ritter & Edwards, 1984;
Stricker et al., 1997). Hence, to further probe the role of the AP in
the control of food intake, we ﬁrst aimed to analyse meal patterns in
our rat model of AP lesions (APX), compared with sham-lesioned
rats. Our second goal was to determine whether equipotent doses of
amylin and sCT activate phenotypically similar neuronal populations
in the AP. To this end, we assessed whether the amylin- or sCT-
induced Fos expression co-localizes with markers for catecholamin-
ergic and serotoninergic neurons. Finally, because glutamatergic
transmission may underlie several effects mediated by noradrenergic
AP neurons (Stornetta et al., 2002), and because this may be rele-
vant for amylin-induced activation of the AP (Fukuda et al., 2013),
we evaluated the apposition of vesicular glutamate transporter-2
(VGLUT2)-positive boutons to neurons co-expressing Fos and DBH
in the AP after amylin or sCT.
Materials and methods
Animals
Male Wistar rats (200–250 g; Charles River, Sulzfeld, Germany)
were maintained at a constant ambient temperature (21  1 °C)
under an artiﬁcial 12 h light/dark cycle with standard chow diet (no.
3430; Provimi Kliba, Gossau, Switzerland) and water available ad
libitum, unless otherwise noted. All experiments were performed
with the approval of the Veterinary Ofﬁce of the Canton Zurich,
Switzerland, and in accordance with the EU Directive 2010/63/EU
on the protection of animals used for scientiﬁc purposes.
Drugs
Amylin and sCT (Bachem AG, Bubendorf, Switzerland; catalog
numbers: amylin H-9475.1000; sCT H-2260.0001) were reconsti-
tuted with sterile 0.9% saline and diluted with saline to ﬁnal doses
of 1, 5 or 10 lg/kg, with an injection volume of 1 mL/kg.
Surgery
Rats were anesthetized intraperitoneally (i.p.) using a mixture of
ketamine (50 mg/kg; Narketan, Vetoquinol AG, Ittingen, Switzer-
land), xylazine (2.5 mg/kg, Xylazin; Streuli Pharma AG, Uznach,
Switzerland) and acepromazine (0.75 mg/kg, Prequillan; Arovet AG,
Dietikon, Switzerland). The head of the rat was ﬂexed ventrally at
an approximate 110 ° angle in a stereotaxic frame. Skin and three
layers of neck musculature were cut and retracted for visualization
of the foramen magnum. Under visual control with a surgical micro-
scope, the cranial dura mater was penetrated with an angled cannula
tip and the cerebrospinal ﬂuid was blotted. AP lesions were per-
formed by aspirating the AP with a blunted cannula tip ﬁxed to a
ﬂexible tube attached to a vacuum pump (Lutz et al., 1998; Jordi
et al., 2013). In sham-lesioned rats, the AP was exposed but not
touched. Musculature and skin were sutured respecting the individ-
ual muscle layers. Rats received subcutaneous injections of 5 mL
sterile saline, antibiotics (7.5 mg/kg enroﬂoxacin, Baytril 2.5%; Pro-
vet AG, Lyssach, Switzerland) and an analgesic (1 mg/kg ﬂunixin,
Fluniximin; Graeub AG, Bern, Switzerland) daily for at least 3 days
post-surgery, and were given 1–2 weeks to recover from surgery. At
the end of the experiments AP lesions were conﬁrmed histologically
(Lutz et al., 1998, 2001; Riediger et al., 2004), in parallel with the
immunohistochemical quantiﬁcation.
Experiment 1: meal pattern analysis in untreated AP-lesioned
and sham-lesioned rats
Meal patterns in sham- and AP-lesioned groups (n = 16 and 13,
respectively) were analysed using the BioDAQ Food Intake Monitor
(Research Diets, New Brunswick, NJ, USA). The technical speciﬁ-
cations of the monitoring system have been described previously
(Boyle et al., 2011). Rats were habituated to a 12-h fast twice per
week followed by 3 days of adaptation to the BioDAQ cages (type
2000P; Tecniplast, Germany). Meal pattern data were collected and
analysed under two conditions. First, eating was recorded for 24 h
in ad libitum-fed rats. Second, 24-h food intake data were collected
after a 12-h fast during the light phase. Meal pattern data collected
from each rat were segmented into meals by clustering independent
feeding bouts. The criteria deﬁning a meal were a minimum inter-
meal interval of 15 min and a minimum meal size of 0.23 g. Data
were analysed using the BioDAQ Monitoring software.
Experiment 2: behavioral experiments: dose–response study
and identification of equipotent eating-inhibitory doses of
amylin and sCT
Sham-lesioned and APX rats were individually housed in hanging
wire mesh cages (Indulab AG, Gams, Switzerland; stainless steel,
47 9 33 9 20 cm) ﬁtted with external food hoppers. Twice per
week, rats were fasted for 12 h during the light phase. Shortly before
dark-onset, rats were injected i.p. with vehicle (0.9% saline), amylin
or sCT; at dark-onset, food was given back. Food intake was mea-
sured manually using a digital scale after 1, 2, 4 and 24 h. Tests were
repeated in a randomized, crossover manner, so that each animal
within the surgery group was examined under all treatment conditions.
The dose–response relationships for amylin and sCT were assessed
using three increasing doses (1, 5, 10 lg/kg). Based on these ﬁndings,
equipotent doses of amylin (10 lg/kg) and sCT (5 lg/kg) were tested
again in a different group of rats, in a second behavioral experiment.
Experiments 3–5: phenotypic characterization of amylin- and
sCT-activated neurons
Rats were fasted for 12 h during the light phase before receiving
injections of vehicle, amylin (10 lg/kg) or sCT (5 lg/kg) at dark-
onset. Food was withheld and, 90 min later, rats were deeply anes-
thetized with pentobarbital (100 mg/kg, i.p.; Cantonal Pharmacy of
Zurich, Switzerland), transcardially perfused with 4% paraformalde-
hyde in 0.1 M phosphate buffer (PB), and brains collected.
Perfused brains were kept in 4% paraformaldehyde for 48 h, fol-
lowed by cryoprotection in 0.1 M PB (pH 7.2) containing 20%
sucrose for 24 h. Brains were then frozen with hexane (Sigma
Aldrich) on dry ice. Six series of 30-lm-thick frontal sections (from
bregma 6.36 mm to 14.40 mm) were cut on a cryostat (Leica
microsystems, Wetzlar, Germany). The sections were kept in a cryo-
protecting medium (50% 0.1 M PB, 30% ethylene glycol, 20% glyc-
erol) at 20 °C until processing for immunohistochemistry. One
series of sections from each brain was processed for the detection of
Fos and DBH, one series for the detection of Fos and tryptophan
hydroxylase (TPH), and one series was processed for the detection
of Fos, DBH and VGLUT2.
Experiment 3: double-immunostaining for Fos and DBH
All rinses were conducted in 0.1 M PB for 10 min. At least four
rinses were implemented between every incubation step. Free-ﬂoating
sections were incubated for 1 h at room temperature in a blocking
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solution of 0.1 M PB containing 1% normal donkey or normal goat
serum (NDS or NGS) and 0.3% Triton-X (Triton X-100; Sigma
Aldrich, Germany). The primary and secondary antibodies were
diluted in 0.1 M PB containing 1% NDS or NGS and 0.3% Triton-X
at concentrations described in Table 1. Sections were incubated in the
two primary antibody solutions for subsequent overnights (beginning
with the Fos antibody) at room temperature, followed by 1-h incuba-
tion in ﬂuorochrome-conjugated secondary antibody solutions at room
temperature. Stained sections were mounted on gelatinized slides and
coverslipped with Citiﬂuor (AF-100; Citiﬂuor, London, UK).
Experiment 4: double-immunostaining for Fos and TPH
All rinses were conducted in 0.1 M PB for 10 min. At least four
rinses were implemented between every incubation step. Free-ﬂoating
sections were blocked for 1 h at room temperature in 0.1 M PB con-
taining 1% NDS and 0.3% Triton-X (Sigma Aldrich). Sections were
incubated overnight at room temperature in the anti-Fos primary anti-
body diluted in 0.1 M PB, 1% NDS and 0.3% Triton-X. Thereafter,
sections were incubated in the corresponding secondary antibody
(Table 1) diluted in 0.1 M PB, 1% NDS and 0.3% Triton-X for 1 h
at room temperature. After the incubation with the secondary anti-
body, the tissue was incubated for 1 h at room temperature in an
Avidin/Biotinylated enzyme Complex (ABC) solution. For visualiza-
tion of Fos-positive cells, sections were incubated in enhanced 3,30-
diaminobenzidine-tetrahydrochloride (DAB) chromogen solution
(0.05% DAB, 0.04% nickel, 0.08% cobalt and 0.3% H2O2 in phos-
phate-buffered saline) for approximately 2–5 min. Next, the tissue
was incubated in the anti-TPH primary antibody overnight at room
temperature and the following day, in the corresponding secondary
antibody for 1 h. To visualize TPH-positive cells, a peroxidase sub-
strate system (ImmPACT NovaRED; Vector Laboratories, Burlin-
game, CA, USA) was used. The sections were incubated in the
peroxidase substrate for 2–5 min, and then rinsed in distilled water
to stop the staining process and wash off the remaining reagents. All
concentrations of antibody and chromogen solutions are shown in
Table 1. Tissue was mounted on gelatinized slides and left to air dry
for up to 1 h. Slides were then dehydrated in an ascending series of
clean alcohols, defatted in xylol and coverslipped with DPX medium
(Fisher Scientiﬁc, Reinach, Switzerland).
Quantification and analysis of double-immunostaining
Photomicrographs of all sections containing AP, medial subnucleus of
the NTS (mNTS), dorsal and central raphe nuclei (DR, CR) were
taken at 20 9 magniﬁcation and a numeric aperture of 0.5, using a
light microscope (Zeiss Imager Z2) ﬁtted with a black and white cam-
era (Zeiss Axiocam HRm) or a color camera (Zeiss Axiocam). Fos-
positive cells were counted using ImageJ software (National Institutes
of Health, Bethesda, MD, USA). All other quantiﬁcations were done
manually in a blinded manner, counting by eye using the digital
images. Sections within the following bregma coordinates were quan-
tiﬁed: 13.56 to 14.40 mm for the AP, 11.76 to –14.40 mm for
the NTSm, 6.36 to 9.36 mm for the DR and CR. For each animal,
the counts from all sections (corresponding to a particular brain area)
were averaged. Final results are reported as group means  SEM. For
the remainder of the manuscript this method of imaging and quantiﬁ-
cation will be referred to as light microscopy.
Experiment 5: triple-immunostaining for Fos, DBH and
VGLUT-2
Rinses were conducted as above. All incubation and blocking steps
were conducted at room temperature. Free-ﬂoating sections were
ﬁrst blocked in sequential blocking solutions consisting of 0.1 M PB
and Avidin (1 : 10) or Biotin (1 : 10), for 15 min each, followed
by blocking in 0.3% Triton-X and 1% NDS in 0.1 M PB for 1 h.
Sections were then incubated overnight in a 0.1 M PB solution con-
taining 0.3% Triton-X, 1% NDS and all three primary antibodies
(anti-Fos, -DBH and -VGLUT2). On the following day, sections
were incubated for 1 h in a solution of 0.1 M PB containing 0.3%
Triton-X, 1% NDS and all three ﬂuorochrome-conjugated secondary
antibodies (Table 1). Stained sections were then mounted on gelati-
nized slides and coverslipped with Citiﬂuor.
Quantification and analysis of triple-immunostaining
In order to have 3D visualization of the VGLUT2-positive boutons
and their proximity to neurons double-labeled for Fos and DBH,
confocal image acquisition was required. Stereological methods were
then applied to these 3D images to quantify the presence of Fos,
DBH and VGLUT2 immunostaining in the entire AP. All brain sec-
tions containing the AP were scanned with a CLSM Leica SP5 Mid
UV-VIS confocal microscope equipped with an x–y–z motorized
stage and lasers appropriate for detecting Cy3, Alexa 488 and Alexa
647 ﬂuorescence. Scans were taken in the tile mode using a 63 9
magniﬁcation and a numeric aperture (oil immersion) of 1.4. The
extent of the AP was marked manually (x/y positions) and the soft-
ware (LASF, advanced ﬂuorescence lite, 2.6.0; Leica microsystems,
Wetzlar, Germany) adjusted the total number of tiles to be scanned.
Table 1. Immunohistochemical reagents
Reagents Antigen/conjugate Host Type Source Catalog no. Dilution
Primary Fos Rb Polyclonal Calbiochem PC38 1 : 10 000
Secondary Anti-rabbit IgG Dk Cy3-labeled Jackson 711-165-152 1 : 400
Secondary Anti-rabbit IgG Dk Biotinylated Jackson 711-065-152 1 : 400
Primary DBH Ms Monoclonal Millipore MAB308 1 : 1000
Secondary Anti-mouse IgG Dk Alexa488-labeled Jackson 715-545-150 1 : 400
Primary TPH Sh Polyclonal Millipore AB1541 1 : 5000
Secondary Anti-sheep IgG Dk Biotinylated Jackson 713-065-003 1 : 400
Primary VGLUT2 Gp Polyclonal Millipore AB5907 1 : 2000
Secondary Anti-guinea pig Dk Alexa647-labeled Jackson 706-605-148 1 : 400
Immune-peroxidase ABC system Vectastain Elite ABC kit Vector PK-6100 1 : 400
Chromagen DAB Sigma D5637 1 : 20
Peroxidase substrate ImmPact NovaRed Vector SK4805
Rb, rabbit; Dk, donkey; Ms, mouse; Sh, sheep; Gp, guinea pig; DAB, 3,30-diaminobenzidine-tetrahydrochloride; DBH, dopamine beta hydroxylase; TPH, trypto-
phan hydroxylase; VGLUT2, vesicular glutamate transporter-2.
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At three randomly chosen x/y coordinates in each section, the thick-
ness of the section was measured manually and then used to deﬁne
the z-height of all tiles to be scanned at z-increments of 0.5 lm. An
overlap of 15% was used for the subsequent stitching of the tiles to
generate a complete 3D image of the AP section.
Using the Optical Fractionator (Stereo Investigator 10; MBF Biosci-
ence, Williston, VT, USA; as described previously by West et al.,
1991), Fos-positive, DBH-positive, Fos- and DBH-double-positive cells
and VGLUT2-positive boutons were counted using a counting frame
size of 80 9 80 lm, a dissector height of 10 lm and a top guard
zone of 2 lm. Only VGLUT2-positive boutons that were abutting a
neuron’s soma were considered. All boutons in apposition to Fos- and
DBH-double-positive cells selected by the optical dissector probe were
counted. Unbiased estimates of the total number of neurons of interest
per AP were acquired by multiplying the counts with the inverse of
the sampling fractions for sections, area and section thickness. This
method of confocal stereological quantiﬁcation will be referred to as
confocal microscopy for the remainder of the manuscript.
Statistics
Statistical analysis was done using Prism (Graph Pad Software,
La Jolla, CA, USA). One-way ANOVA and Student’s t-tests were used
as described below. One-way ANOVA analyses were followed by
Bonferroni post hoc tests, when appropriate. A P-value of < 0.05
was considered statistically signiﬁcant for all experiments.
 Experiment 1: t-tests; sham vs. APX within ad libitum or post-
deprivation conditions, n = 13–17 per surgery group.
 Experiment 2: one-way ANOVA; treatment as main factor, within
surgery (APX or sham) condition, per time point, n = 11–13 per
surgery group.
 Experiment 3: one-way ANOVA; treatment as main factor, within
surgery (APX or sham) condition, n = 13–17 per surgery group.
 Experiment 4: one-way ANOVA; treatment as main factor, within
surgery (APX or sham) condition, n = 13–17 per surgery group.
 Experiment 5: t-tests; amylin 10 lg/kg vs. sCT 5 lg/kg within
sham-lesioned rats, n = 5–6 per treatment group.
 Experiment 6: t-tests; comparison of quantitative analysis using
confocal microscopy vs. light microscopy within treatment condition
(amylin 10 lg/kg or sCT 5 lg/kg), n = 5–6 per treatment group.
Results
Experiment 1: meal pattern analysis of sham and APX rats
APX rats exhibited altered meal patterns indicative of a change in
feedback inhibition of ingestive behavior. Under ad libitum conditions,
the size of the ﬁrst meal was signiﬁcantly larger in APX than sham
rats (t26 = 5.425, P < 0.001), but APX rats took longer after dark-
onset to initiate the ﬁrst meal (t26 = 3.028, P = 0.006). Average meal
size (t26 = 3.870, P < 0.001) as well as average meal duration
(t26 = 2.192, P = 0.038) were signiﬁcantly increased in APX com-
pared with sham rats. Although sham rats ate more meals per day than
APX rats (t26 = 3.564, P = 0.001), the inter-meal interval was not sig-
niﬁcantly different. Total 24-h food intake did not differ between sham
and APX rats (Table 2).
In the post-deprivation condition following a 12-h light-phase
fast, food intake of APX rats in the following 24 h was signiﬁcantly
reduced compared with sham (t26 = 3.128, P = 0.004). Similar to
ad libitum conditions, APX rats consumed signiﬁcantly fewer meals
(t26 = 5.728, P < 0.0001) and their latency to feed after dark-onset
was longer (t26 = 5.650, P < 0.0001). Average meal size, meal
duration, size of ﬁrst meal and the inter-meal interval did not differ
signiﬁcantly between the two surgery groups in this state, which
was largely due to a deprivation-induced increase in meal size in the
sham group that was not observed in the APX group.
Experiment 2.1: dose–response curve
As previously reported (Lutz et al., 2000), amylin and sCT dose-depen-
dently decreased eating in sham rats (Fig. 1A and C). Eating was sig-
niﬁcantly decreased by 5 and 10 lg/kg amylin at the 1-h time point
(F3,12 = 7.034, P < 0.01), and by 10 lg/kg amylin at the 2-h time
point (F3,12 = 5.941, P < 0.01). A dose of 1 lg/kg amylin had no
effect on eating, and none of the doses decreased eating at the 4-h time
point (F3,12 = 1.415, P > 0.05). Amylin did not decrease eating in
APX rats at any dose or time point (F3,12 = 0.4145, 0.6527 and 0.9649,
for 1-, 2- and 4-h time points, respectively, P > 0.05 for all; Fig. 1B).
Compared with saline and 1 lg/kg sCT, 5 and 10 lg/kg sCT
reduced food intake at all times (F3,14 = 38.07, 40.16, 67.14 and
401.6 for 1-, 2-, 4- and 24-h time points, respectively, P < 0.001)
in sham rats. Doses of 5 and 10 lg/kg sCT were not signiﬁcantly
different from each other. A dose of 1 lg/kg sCT decreased eating
only at 4 and 24 h post-injection (F3,14 = 67.14 and 401.6, for
4- and 24-h time points, respectively, P < 0.001). The AP lesion
almost completely blocked the effect of sCT on eating. However,
after receiving 5 lg/kg sCT, 4-h food intake in APX rats was signif-
icantly reduced, as shown by a one-way ANOVA and subsequent Bon-
ferroni post hoc analysis (4-h; F3,13 = 3.545, P < 0.05; Fig. 1D).
Experiment 2.2: equipotent doses of amylin and sCT
Figure 2A shows the signiﬁcant food intake reduction after amylin
and sCT in sham rats; in the ﬁrst hour after injection, 10 lg/kg
amylin and 5 lg/kg sCT reduced food intake to a similar extent
Table 2. Mean  SEM meal parameters measured in sham and APX rats under ad libitum conditions and following a 12-h light phase fast
Ad libitum Post-deprivation
Sham
mean  SEM
APX
mean  SEM P-values
Sham
mean  SEM
APX
mean  SEM P-values
Total food intake/24 h (g) 28.0  0.7 28.1  1.8 0.9438 31.4  1 23.2  2.7 0.0042
Total meal number/24 h 8.0  0.4 5.9  0.5 0.0014 7.7  0.4 4.6  0.3 < 0.0001
Average meal size (g) 3.6  0.2 5.0  0.3 0.0007 4.3  0.3 5.4  0.5 0.0537
Meal duration (min) 30.6  2.9 41.5  4.3 0.0375 37.2  4.5 44.9  4.2 0.2360
First meal size (g) 2.7  0.2 5.4  0.5 <0.001 5.5  0.7 5.2  0.5 0.7456
Inter-meal interval (min) 65.8  5.3 60.9  6.9 0.5785 75.1  6.1 82.3  20.8 0.7099
Latency to feed (min) 10.3  3.9 47.7  13.3 0.0055 1.2  0.3 60.6  12.2 < 0.0001
APX, area postrema lesion.
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(F2,16 = 13.17, P < 0.001), and there was no signiﬁcant difference in
the eating-inhibitory effect of the two peptides at this time point. Two
and 4 h after injection, only sCT but not amylin reduced eating. In
the APX rats (Fig. 2B), neither peptide evoked a signiﬁcant reduction
of the cumulative food intake in the ﬁrst 2 h. However, there was
a signiﬁcant difference 4 h after the injection between sCT and amy-
lin, but not vehicle controls (one-way repeated-measures ANOVA and
Bonferroni post hoc analysis; F2,12 = 7.112, P < 0.01).
Experiment 3: co-localization of Fos- and DBH-positive
neurons in the AP and NTS
Amylin and sCT induced Fos in DBH-expressing neurons in the
AP and NTS, as depicted in Fig. 3A–D. One-way ANOVA followed
by a Bonferroni post hoc analysis revealed that 5 lg/kg of sCT pro-
duced signiﬁcantly more Fos-positive cells (F2,14 = 122.7, P < 0.05)
and neurons double-labeled for Fos and DBH than 10 lg/kg
of amylin (F2,14 = 71.7, P < 0.05) in the AP (Fig. 4A). Relative
co-activation was similar, with approximately 44% of the amylin-
induced and 47% of the sCT-induced Fos-positive neurons being
also positive for DBH; there was no difference between these per-
centages (t5 = 0.7585, P = 0.4823). Further, there was no signiﬁcant
difference in number of DBH-positive cells across the treatment
groups (F2,14 = 1.431, P = 0.272; Fig. 4A).
Compared with vehicle, both amylin and sCT treatment resulted
in a signiﬁcant increase in Fos in the NTS of sham rats
(F2,14 = 12.36, P < 0.001; Fig. 4B). Amylin (10 lg/kg) led to a
higher number of double-stained neurons (F2,14 = 14.53, P < 0.05)
and a greater number of DBH-positive cells than sCT (5 lg/kg;
F2,14 = 12.45, P < 0.01). Overall, the percentage of co-localization
was much lower than in the AP. Neither amylin nor sCT induced
Fos expression in the NTS of AP-lesioned rats (Fig. 4C). There was
A B
C D
Fig. 1. Amylin and salmon calcitonin (sCT) lead to a dose-dependent reduction in cumulative food intake; the effect of sCT was more potent and longer last-
ing. Mean  SEM cumulative food intake 1, 2, 4 and 24 h after injection of vehicle, amylin (1, 5 or 10 lg/kg; A, B) or sCT (1, 5 or 10 lg/kg; C, D) in
sham-lesioned (A, C) and area postrema-lesioned (APX) rats (B, D). *Signiﬁcantly different from vehicle P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001; °°°signiﬁcantly
different from 1 lg/kg P ≤ 0.001.
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Fig. 2. Amylin (10 lg/kg) and salmon calcitonin (sCT; 5 lg/kg) reduced
cumulative food intake similarly in sham rats in the ﬁrst hour after injection
compared with vehicle. Neither amylin nor sCT reduced eating in area pos-
trema-lesioned (APX) rats compared with control. Mean  SEM cumulative
food intake 1, 2 and 4 h after injection of vehicle, amylin (10 lg/kg) or sCT
(5 lg/kg) in sham-lesioned (A) and APX rats (B). **Signiﬁcantly different
from vehicle P ≤ 0.01, ***P ≤ 0.001; °°signiﬁcantly different from amylin
(10 lg/kg) P ≤ 0.01, °°°P ≤ 0.001.
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no signiﬁcant difference in the number of DBH-positive cells
between the treatment groups (F2,10 = 3.357, P = 0.0766).
Experiment 4: co-localization of Fos- and TPH-positive
neurons in brainstem nuclei
Amylin (10 lg/kg) and sCT (5 lg/kg) signiﬁcantly increased the
number of Fos-positive cells in the AP compared with vehicle
(one-way ANOVA and Bonferroni post hoc analysis; F2,14 = 67.25,
P < 0.0001); however, no TPH-positive neurons were detected in
either group (Fig. 5A). Amylin (10 lg/kg) and sCT (5 lg/kg) signiﬁ-
cantly increased the number of Fos-positive cells in the NTS of
sham-lesioned rats (F2,14 = 18.35, P = 0.0001; Fig. 5B). Amylin
and sCT treatment did not signiﬁcantly alter the number of TPH-posi-
tive cells in the NTS of sham rats, and there was no appreciable over-
lap of Fos and TPH staining in any of the three groups. Following
APX (Fig. 5C), the number of amylin- and sCT-induced Fos-positive
cells in the NTS was indistinguishable from vehicle-treated rats.
One-way ANOVA analysis suggested that a constitutive amount of
Fos, TPH and a low degree of co-localization (Table 3) of these two
A B
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E
Fig. 3. Amylin and salmon calcitonin (sCT) induced Fos in dopamine beta hydroxylase (DBH)- but not tryptophan hydroxylase (TPH)-expressing neurons in
brainstem nuclei. Representative images showing co-localization of Fos- (red nuclei) and DBH-expressing (green cell bodies) neurons in the area postrema (AP)
and nucleus of the solitary tract (NTS) of sham rats after saline (A), amylin (10 lg/kg; B) or sCT (5 lg/kg; C) treatment, and in an AP-lesioned (APX) rat after
amylin (10 lg/kg; D). Representative images showing minimal co-localization of Fos- (black nuclei) and TPH-expressing (dark orange cell bodies and processes)
neurons in the dorsal raphe nucleus (DR) of sham (E) and APX (F) rats treated with 5 lg/kg sCT; the inset in (F) shows an example of one neuron co-expressing
Fos and TPH (black arrow). Representative images showing the co-localization of Fos (red nuclei), DBH (green cell bodies) and vesicular glutamate transporter-2
(VGLUT2; cyan boutons) in the AP of sham rats treated with 10 lg/kg amylin (G) or 5 lg/kg sCT (H). The inset shows a high-magniﬁcation confocal scan of
AP from sham rat treated with 5 lg/kg sCT showing an example of VGLUT2 bouton (white arrow) apposed to a neuron co-expressing Fos and DBH (I). AQ,
cerebral aqueduct; C, central canal; mlf, medial longitudinal fascicle; NTSm, medial subnucleus of the nucleus of the solitary tract; 4V, fourth ventricle.
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markers seemed to be present in the DR and CR (Fig. 3E and F),
independent of treatment and surgery (sham vs. APX).
Experiment 5: co-localization of Fos- and DBH-positive
neurons apposed to VGLUT2-positive boutons in the AP
Confocal microscopy analysis revealed that rats treated with sCT
exhibited a signiﬁcantly greater number of Fos-positive cells in the AP
compared with amylin-treated rats (t9 = 3.157, P = 0.0116; Fig. 6A),
this coincides with the results acquired with the standard light microscopy
method. Confocal analysis also revealed that amylin and sCT did not alter
the number of DBH-positive cells in the AP (t9 = 0.3311, P = 0.7482;
Fig. 6B). There was a signiﬁcant difference in the number of double-
labeled cells between amylin and sCT (t9 = 3.094, P = 0.0128), as
shown in Fig. 6C, but the percentage of co-localization did not differ
between amylin and sCT. Furthermore, there was no signiﬁcant differ-
ence in the total number of VGLUT2-positive boutons (t9 = 2.082,
P = 0.067; Fig. 6D) or the number of VGLUT2-positive boutons per
double-labeled cell (t9 = 0.5655, P = 0.5855; Fig. 6E) when comparing
sCT- and amylin-treated groups. In amylin-treated sham rats, an average
of 94.6% of all cells co-expressing Fos and DBH were apposed to
VGLUT2-positive boutons, vs. a mean of 95.2% for sCT; these percent-
ages did not differ signiﬁcantly (t9 = 0.2411, P = 0.8149). Representa-
tive confocal images are shown in Fig. 3G–I.
Based on the Gunderson–Jensen estimator (Gundersen et al.,
1999), using a smoothness constant of 1 for the AP, the ratio
between mean CE2 and the observed relative variance CV2 was
< 0.5 for all the markers estimated, demonstrating that the sampling
procedure contributed only little to the observed group variances.
Experiment 6: comparison of the two methods of quantification
When comparing the results obtained with confocal microscopy with
those obtained with light microscopy, we did not detect a signiﬁcant
difference in the percentage of Fos cells that were double-labeled
for Fos and DBH following amylin (t5 = 0.1353, P = 0.8977) or
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Fig. 4. Amylin and salmon calcitonin (sCT)-induced Fos co-localizes with
dopamine beta hydroxylase (DBH)-positive neurons in the area postrema
(AP) and nucleus of the solitary tract (NTS) of sham rats. Mean  SEM
number of Fos-positive, DBH-positive and double-labeled cells in the AP
(A) and NTS (B) of sham rats, and the NTS of AP-lesioned (APX) rats (C)
after treatment with vehicle, amylin (10 lg/kg) or sCT (5 lg/kg). **Signiﬁ-
cantly different from vehicle P ≤ 0.01, ***P ≤ 0.001; °signiﬁcantly different
from amylin (10 lg/kg) P ≤ 0.05, °°P ≤ 0.01.
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Fig. 5. Amylin and salmon calcitonin (sCT)-induced Fos does not co-local-
ize with tryptophan hydroxylase (TPH)-positive neurons in the area postrema
(AP) and nucleus of the solitary tract (NTS) of sham rats. Mean  SEM
number of Fos-positive, TPH-positive and double-labeled cells in the AP (A)
and NTS (B) of sham rats, and the NTS of AP-lesioned (APX) rats (C) after
treatment with vehicle, amylin (10 lg/kg) or sCT (5 lg/kg). **Signiﬁcantly
different from vehicle P ≤ 0.01, ***P ≤ 0.001.
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sCT treatment (t4 = 0.131, P = 0.9021), as depicted in Fig. 7A.
However, the light microscopy method appeared to underestimate
the portion of DBH cells that co-express Fos, compared with confo-
cal microscopy, in both amylin- (t5 = 3.496, P = 0.0174) and
sCT-treated groups (t4 = 5.703, P = 0.0047; Fig. 7B).
Discussion
The AP is a critical brain area for the control of homeostatic nutrient
handling. The AP relays information relating to gastric emptying,
mediates the formation of conditioned taste aversion, and expresses
receptors for many metabolic hormones including amylin, glucagon-
like peptide-1 (GLP-1) and ghrelin (Edwards et al., 1998; Fry &
Ferguson, 2009; Punjabi et al., 2011; Zuger et al., 2013). The pur-
pose of the present study was threefold. First, we characterized meal
patterns in sham- and AP-lesioned rats under ad libitum and post-
deprivation conditions. Second, we sought to clarify the role of the
AP in sCT-induced anorexia over a range of doses, relative to the
effect of amylin. Finally, we examined and compared the phenotype
of brainstem neurons expressing amylin- and sCT-induced Fos, and
thereby used for the ﬁrst time the confocal microscopy approach to
quantify cells in the AP.
Over the course of our experiments, and consistent with previous
work done in our laboratory, it became evident that when using
APX rats for behavioral experiments, which involved 12-h fasting,
rats did not react the same way as their sham controls. APX rats
had a long latency to eat and some did not start eating for up to 4 h
into the dark phase. Earlier work with AP-lesioned rodents sug-
gested that the AP plays a crucial role in the detection of inhibitory
signals triggered by food or ﬂuid ingestion, and that ingestive bouts
increase in size after APX because the inhibitory feedback is blunted
(Stricker et al., 1997). It has also been proposed that because total
daily food intake is similar in control and APX rats, APX disrupts
the short-term control of meal pattern but not the long-term control
of caloric intake in association with body weight maintenance (Ritter
& Edwards, 1984). Consistent with these ﬁndings, our analysis of
meal patterns showed that although APX and sham rats consumed
comparable amounts of chow per day under ad libitum conditions,
there were differences in how their meals were structured and how
the two groups responded to a 12-h light phase fast. Under ad libi-
tum conditions, APX ate larger but fewer meals compared with
sham rats. Further, we observed that APX rats ingested a larger ﬁrst
meal after dark-onset than sham rats, but the latency to do so was
much longer. After fasting the rats for 12 h during the light phase,
sham rats compensated by eating more food over the subsequent 24-
h period than under ad libitum conditions. They did so by increasing
their average meal size and reducing the latency to feed after the
fast. In contrast, the meal proﬁle in APX rats remained almost unal-
Table 3. Mean  SEM number of Fos-positive, TPH-positive and double-labeled cells in the DR and CR of sham and APX rats after treatment with vehicle,
amylin (10 lg/kg) or sCT (5 lg/kg)
Sham APX
Vehicle
mean  SEM
Amylin 10 lg/kg
mean  SEM
sCT 5 lg/kg
mean  SEM
Vehicle
mean  SEM
Amylin 10 lg/kg
mean  SEM
sCT 5 lg/kg
mean  SEM
DR
Fos-positive 9.6  4.3 20.3  5.2 7.2  2.4 6.5  2.5 19.6  6.6 12.0  7.4
Double-labeled (Fos + TPH) 2.4  1.3 8.2  3.0 1.8  0.6 0.9  0.5 4.9  2.4 4.5  3.1
TPH-positive 100.6  5.7 117.7  12.1 114.6  22.7 116.4  13.6 109.0  13.2 101.9  13.1
CR
Fos-positive 4.4  2.4 8.1  3.0 3.5  1.2 4.0  1.8 10.7  4.7 7.5  3.0
Double-labeled (Fos + TPH) 1.1  0.7 2.4  0.8 1.6  0.8 0.4  0.1 2.5  1.2 1.1  0.6
TPH-positive 49.6  7.5 57.1  3.9 53.6  5.7 49.6  2.9 54.9  1.8 49.7  3.7
APX, area postrema lesion; CR, central raphe nucleus; DR, dorsal raphe nucleus; sCT, salmon calcitonin; TPH, tryptophan hydroxylase.
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Fig. 6. Using confocal microscopy, approximately 50% of Fos-positive cells were also dopamine beta hydroxylase (DBH)-positive after amylin (10 lg/kg) and
salmon calcitonin (sCT; 5 lg/kg), and there was a similar apposition of vesicular glutamate transporter-2 (VGLUT2)-positive boutons in amylin- (10 lg/kg)
and sCT- (5 lg/kg) treated sham rats. Mean  SEM unbiased estimation of the number of Fos-positive cells (A), DBH-positive cells (B), and Fos and DBH
double-labeled cells (C) in the entire AP of sham rats treated with 10 lg/kg amylin or 5 lg/kg sCT, as quantiﬁed using confocal microscopy. Mean  SEM
unbiased estimation of the total number of VGLUT2-positive boutons apposed to neurons co-expressing Fos and DBH (D), and the average number of
VGLUT2-positive boutons per double-labeled cell (E) in the entire AP of sham rats treated with 10 lg/kg amylin or 5 lg/kg sCT. +Signiﬁcantly different from
amylin (10 lg/kg) P ≤ 0.05.
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tered by the metabolic challenge; APX rats consumed even fewer
meals than under ad libitum conditions and ate less over the subse-
quent 24 h. Hence, APX rats appeared unaffected by the preceding
caloric deﬁcit.
It was initially suggested that the disruption in ingestive patterns
following AP lesions was a result of the loss of signals of gastric
distention (Stricker et al., 1997). Today we know that ablation of
the AP not only thwarts a major relay station for vagal and splanch-
nic sensory information passing from the viscera to the brain, but
also destroys several neuronal populations responsive to various
hormones controlling food intake. Ablation of AP neurons prevents
amylin-induced satiation thus increasing meal size (Lutz et al., 1998;
Reidelberger et al., 2002; Potes et al., 2010b). The loss of AP neu-
rons carrying GLP-1 receptors (Yamamoto et al., 2003), which likely
constitute a neuronal population discrete from amylin-responsive neu-
rons (Zuger et al., 2013), is another potential contributor to the large
extended meals observed following APX. The loss of a third receptor
population could explain the increased latency to feed under both ad
libitum and post-deprivation conditions. Ghrelin receptors are also
present in the AP (Zigman et al., 2006), and APX was previously
shown to blunt ghrelin’s orexigenic effect in rats at least under cer-
tain conditions (Gilg & Lutz, 2006). Further, ghrelin exerts a direct
effect on the electrical activity of a subpopulation of AP neurons
(Fry & Ferguson, 2009). Ghrelin signaling in the AP might be criti-
cal for both normal meal initiation and for enhancing food seeking
and consumption after a fast. We suggest that the lack of ghrelin sig-
naling might lead to the delayed initiation to feed in APX rats. A
schematic of these AP neuronal populations is presented in Fig. 8.
In addition to the effects on hormone sensing, lesioning the AP
also disrupts perception of various nutrients that can modify food
intake. Not only have glucose-responsive neurons in the AP been
identiﬁed (Adachi et al., 1995), but the majority of amylin-sensitive
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Fig. 7. Compared with confocal microscopy, light microscopy underesti-
mated the degree of dopamine beta hydroxylase (DBH)-expressing neurons
that also express Fos, but not Fos-expressing neurons that also express DBH.
Mean  SEM percentage of total Fos-positive cells that co-localize with
DBH (A) and the percentage of total DBH-positive cells that co-localize with
Fos (B) in the area postrema (AP) of sham rats treated with 10 lg/kg amylin
or 5 lg/kg salmon calcitonin (sCT), as calculated using light microscopy and
confocal microscopy methods of analysis. *Signiﬁcantly different from light
microscopy P ≤ 0.05, **P ≤ 0.01.
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Fig. 8. Evidence-based schematic of phenotypes of neuronal populations in the area postrema (AP). Amylin- and salmon calcitonin (sCT)-activated neurons, as
shown by Fos expression (red nucleus), can be dopamine beta hydroxylase (DBH)-positive (approximately 50%; green neurons in A) or unidentiﬁed (gray neu-
rons in B), but do not express tryptophan hydroxylase (TPH). Some of the unidentiﬁed neurons could also be second-order neurons. Of the DBH neurons acti-
vated by amylin or sCT (A), 95% are apposed to vesicular glutamate transporter-2 (VGLUT2) boutons (cyan terminals), suggesting a glutamatergic input,
possibly of vagal origin (Kalia & Sullivan, 1982). The amylin-activated neurons project to the nucleus of the solitary tract (NTS) and parabrachial nucleus
(PB), where they hypothetically secrete catecholamines and glutamate (Stornetta et al., 2002; Potes et al., 2010a,b); these neurons can also respond to glucose
(not shown; Riediger et al., 2002). A third population of neurons express glucagon-like peptide-1 (GLP-1) receptors (blue) and are also DBH-positive (green
neurons in C; Yamamoto et al., 2003), but are likely distinct from the amylin-activated, catecholaminergic neurons because GLP-1-activated neurons do not
express calcitonin receptor (CTR; Zuger et al., 2013). These neurons project to the NTS, PB and ventrolateral medulla (RVLM) where they secrete catecholam-
ines and glutamate (Stornetta et al., 2002; Yamamoto et al., 2003). Finally, a population of neurons responsive to ghrelin has also been identiﬁed (D; Fry &
Ferguson, 2009). The phenotype of these neurons is not known; however, the ghrelin receptor (pink) does not co-localize to catecholaminergic neurons in the
AP (Zigman et al., 2006). At present, it is unknown if unidentiﬁed neurons activated by amylin and sCT (B) also bear ghrelin receptors.
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neurons in the AP are also activated by glucose (Riediger et al.,
2002). Further, elegant new studies show that fasting-induced reduc-
tion of blood glucose actually promotes diffusion of blood-borne
metabolic substrates, such as glucose, into the brain through changes
in blood vessel fenestration and reorganization of tight junction
complexes in the median eminence (Langlet et al., 2013a). The AP
is structurally similar to the median eminence, displaying a network
of tanycyte-like cells and fenestrated capillaries (Langlet et al.,
2013b), and could potentially display similar plasticity during a
metabolic challenge like fasting (Prevot et al., 2013). If substrate
receptivity of the AP does indeed depend on nutritional status, abla-
tion of AP neurons would have clear ramiﬁcations on an organism’s
ability to sense and respond to a metabolic deﬁcit, as we have
shown herein. Finally, it was also recently shown that certain indi-
vidual amino acids are capable of reducing food intake, but require
an intact AP (Jordi et al., 2013). The inability to sense these collec-
tive signals following APX likely contributes to the disruption of
both spontaneous eating and the adaptive response to fasting.
In the second part of our studies, we found that, similar to amy-
lin, an intact AP was necessary to produce the full anorectic action
of sCT, conﬁrming previous ﬁndings (Lutz et al., 2001). Results
from the dose–response study showed that at higher doses, sCT is
capable of reducing food intake to a certain extent in APX rats.
Thus, while sCT acting on the AP appears to be the primary route
of action, we cannot rule out the possibility that sCT may also
reduce food intake though an AP-independent mechanism or that a
few remaining intact AP neurons are sufﬁcient to mediate some
reduction in eating after higher doses of sCT. A recent study sug-
gests that the ventral tegmental area (VTA), a key brain center for
reward processing, not only expresses all components of the amylin
receptor, but also seems to play a role in the direct mediation of the
effects of peripheral sCT on food intake (Mietlicki-Baase et al.,
2013); it was observed that local VTA administration of an amylin
antagonist increased food intake and partly prevented the eating
inhibitory effect of peripheral sCT. Therefore, in parallel to the
immunohistochemical studies described here, we also analysed an
additional series of tissue sections for the co-localization of the
enzyme catalysing dopamine synthesis, tyrosine hydroxylase (TH)
and Fos activation in AP- and sham-lesioned rats treated with either
10 lg/kg of amylin, 5 lg/kg of sCT or vehicle. Although TH-posi-
tive neurons were abundant in the VTA of all groups, no Fos was
detected under our conditions (unpublished data). These data suggest
that further investigation is required to determine the role of the
VTA following peripheral treatment with amylin or sCT.
Despite the use of equipotent eating-inhibitory doses, sCT treat-
ment produced a signiﬁcantly higher number of Fos-positive neu-
rons in the AP than amylin when analysed with either light or
confocal analysis. This difference was likely the result of the ability
of sCT to bind irreversibly and with higher afﬁnity to amylin-bind-
ing sites. Given the high afﬁnity of sCT, but not amylin, for the
CTR subunit in the absence of RAMPs (Christopoulos et al., 1999),
theoretically, sCT could activate additional AP neurons expressing
only the CTR subunit. However, emerging data from our lab show
that 100% of single cells collected from the AP that express CTR
also express RAMP1, RAMP3 or both subunits, suggesting that
such a CTR-only population is not present in the AP (Liberini et al.,
2013). Despite increased activation in the AP, no difference in Fos
was observed between sCT and amylin at the level of the NTS, and
APX blocked all NTS Fos activation by both amylin and sCT.
These results demonstrate that the NTS is a downstream relay of the
AP neurons that mediates amylin and sCT eating-inhibitory activity.
The neurotransmitters involved in this relay remain to be deter-
mined, however. The vast majority of AP neurons immunoreactive
for TH also express VGLUT2 mRNA (Stornetta et al., 2002), sug-
gesting that these catecholaminergic neurons are indeed glutamater-
gic as well. Thus, it is possible that induction of Fos in the NTS is
dependent upon glutamatergic input from AP neurons carrying the
amylin receptor, but this has not been tested directly.
In addition to comparing Fos activation after amylin and sCT
treatment, we also investigated if sCT recruited phenotypically dif-
ferent AP or NTS neurons than amylin. Conﬁrming previously pub-
lished results from our group, we found that approximately 50% of
amylin-activated neurons in the AP are noradrenergic (Potes et al.,
2010b). Consistent with increased Fos expression, a slightly larger
total number of sCT-induced Fos neurons co-expressed DBH, com-
pared with amylin. Further, it has been suggested previously that an
intact serotonergic system is necessary for calcitonin-induced analge-
sia (Ormazabal et al., 2001). Because sCT also activates CTRs, we
therefore sought to determine if this system plays a role in other
actions, like the suppression of food intake. However, we observed
almost no overlap between the expression of Fos and TPH in the
AP, NTS, DR or CR. These ﬁndings support earlier results suggest-
ing that the serotonergic system does not seem to mediate amylin-
induced satiation (Lutz et al., 1996; Brunetti et al., 2002), and
further demonstrate that activation of these serotonergic neurons is
not necessary for sCT to suppress eating.
In the last part of our study, we employed confocal microscopy and
stereology to reﬁne our study of neuronal activation patterns of the
entire AP. First, we determined the apposition of VGLUT2-positive
boutons to amylin- and sCT-activated neurons. While not speciﬁcally
identiﬁed in this study, glutamatergic input to the AP likely arises pri-
marily from vagal afferents (Kalia & Sullivan, 1982), and possibly also
from the NTS (Potes et al., 2010a). A difference in the number of
VGLUT2 boutons per activated neuron, which may suggest a differ-
ence in the excitatory drive to this population of AP neurons, could
potentially contribute to the stronger and in particular the longer
inhibition of feeding observed after sCT, compared with amylin. How-
ever, we found that almost all (approximately 95%) amylin- and sCT-
activated neurons were in contact with VGLUT2 boutons, and we did
not observe a difference between amylin and sCT in the number of
VGLUT2 appositions per double-labeled neuron. These results suggest
that, at least following acute treatment, there is no difference in gluta-
matergic apposition between neurons activated by amylin or sCT. We
did not determine if chronic treatment of amylin or sCT would modify
the glutamatergic drive of these populations. Finally, we used the
confocal method to estimate the co-expression of amylin- and sCT-
induced Fos and DBH labeling across the whole AP. To our knowl-
edge, this is the ﬁrst attempt to determine an absolute quantiﬁcation of
Fos-, DBH- and VGLUT2-positive neurons in the AP. This analysis
validated our light microscopy method of analysis, conﬁrming that
about 50% of amylin- and sCT-induced Fos-positive neurons co-local-
ize with DBH. The traditional light microscopy approach did, however,
underestimate the number of DBH neurons co-expressing Fos, which
likely results from the inability to clearly distinguish closely apposed
DBH-positive neurons in the z-plane without confocal imaging.
The results from our current study underscore the role of the AP
in controlling short-term food intake. The meal pattern analysis
showed that a lesion of the AP disrupts the negative feedback sig-
nals controlling meal size and seems to affect the ability to com-
pensate for an energy deﬁcit following a fast. Further, we found
that, like amylin, sCT requires an intact AP to produce its full
effect on food intake and to induce Fos in the NTS. We observed
that neither peptide induced Fos in TPH-expressing neurons in the
NTS, DR or CR, and detected no difference in the number of
© 2014 Federation of European Neuroscience Societies and John Wiley & Sons Ltd
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VGLUT2 boutons apposed to amylin- or sCT-activated neurons
expressing DBH. Use of confocal microscopy conﬁrmed that, like
amylin, approximately 50% of sCT-activated neurons in the AP are
noradrenergic. The phenotype of the remaining Fos-positive neu-
rons in the AP remains to be deﬁned. A summary of our ﬁndings,
in relation to the existing literature, is depicted in Fig. 8. Our study
demonstrates that amylin and its agonist sCT activate similar neuro-
nal populations, suggesting that the difference in anorexic potency
between the peptides primarily results from differences in binding
afﬁnity and receptor dissociation.
Acknowledgements
This work was supported by Novo Nordisk and the Swiss National Science
Foundation, and LA was supported by NIH DK 092608. The authors grate-
fully acknowledge the technical guidance and assistance of Dr Lutz Slomian-
ka, Dr Kathrin Abegg and Dr Urs Ziegler. Imaging was performed with
support of the Center for Microscopy and Image Analysis, University of Zur-
ich.
Abbreviations
AP, area postrema; APX, area postrema lesion/lesioned; CR, central raphe
nucleus; CTR, calcitonin receptor; DAB, 3,30-diaminobenzidene-tetrahydro-
chloride; DBH, dopamine beta hydroxylase; DR, dorsal raphe nucleus; GLP-
1, glucagon-like peptide-1; i.p., intraperitoneal; NDS, normal donkey serum;
NGS, normal goat serum; NTS, nucleus of the solitary tract; NTSm, medial
subnucleus of the nucleus of the solitary tract; PB, phosphate buffer; RAMP,
receptor activity-modifying protein; sCT, salmon calcitonin; TH, tyrosine
hydroxylase; TPH, tryptophan hydroxylase; VGLUT2, vesicular glutamate
transporter-2; VTA, ventral tegmental area.
References
Adachi, A., Kobashi, M. & Funahashi, M. (1995) Glucose-responsive
neurons in the brainstem. Obes. Res., 3(Suppl. 5), 735S–740S.
Barth, S.W., Riediger, T., Lutz, T.A. & Rechkemmer, G. (2004) Peripheral
amylin activates circumventricular organs expressing calcitonin receptor
a/b subtypes and receptor-activity modifying proteins in the rat. Brain
Res., 997, 97–102.
Boyle, C.N., Lorenzen, S.M., Compton, D. & Watts, A.G. (2012) Dehydra-
tion-anorexia derives from a reduction in meal size, but not meal number.
Physiol. Behav., 105, 305–314.
Brunetti, L., Recinella, L., Orlando, G., Michelotto, B., Di Nisio, C. & Vac-
ca, M. (2002) Effects of ghrelin and amylin on dopamine, norepinephrine
and serotonin release in the hypothalamus. Eur. J. Pharmacol., 454, 189–
192.
Butler, P.C., Chou, J., Carter, W.B., Wang, Y.N., Bu, B.H., Chang, D.,
Chang, J.K. & Rizza, R.A. (1990) Effects of meal ingestion on plasma
amylin concentration in NIDDM and nondiabetic humans. Diabetes, 39,
752–756.
Christopoulos, G., Perry, K.J., Morﬁs, M., Tilakaratne, N., Gao, Y., Fraser,
N.J., Main, M.J., Foord, S.M. & Sexton, P.M. (1999) Multiple amylin
receptors arise from receptor activity-modifying protein interaction with
the calcitonin receptor gene product. Mol. Pharmacol., 56, 235–242.
Edwards, G.L., Gedulin, B.R., Jodka, C., Dilts, R.P., Miller, C.C. & Young, A.
(1998) Area postrem (AP)-lesions block the regulation of gastric emptying
by amylin. Neurogastroent. Motil., 10, 26.
Fry, M. & Ferguson, A.V. (2009) Ghrelin modulates electrical activity of
area postrema neurons. Am. J. Physiol.-Reg. I., 296, R485–R492.
Fukuda, T., Hirai, Y., Maezawa, H., Kitagawa, Y. & Funahashi, M. (2013)
Electrophysiologically identiﬁed presynaptic mechanisms underlying amy-
linergic modulation of area postrema neuronal excitability in rat brain
slices. Brain Res., 1494, 9–16.
Gilg, S. & Lutz, T.A. (2006) The orexigenic effect of peripheral ghrelin dif-
fers between rats of different age and with different baseline food intake,
and it may in part be mediated by the area postrema. Physiol. Behav., 87,
353–359.
Gundersen, H.J., Jensen, E.B., Kieu, K. & Nielsen, J. (1999) The efﬁciency
of systematic sampling in stereology–reconsidered. J. Microsc., 193, 199–
211.
Jordi, J., Herzog, B., Camargo, S.M., Boyle, C.N., Lutz, T.A. & Verrey, F.
(2013) Speciﬁc amino acids inhibit food intake via the area postrema or
vagal afferents. J. Physiol., 591, 5611–5621.
Kalia, M. & Sullivan, J.M. (1982) Brainstem projections of sensory and
motor components of the vagus nerve in the rat. J. Comp. Neurol., 211,
248–265.
Langlet, F., Levin, B.E., Luquet, S., Mazzone, M., Messina, A.,
Dunn-Meynell, A.A., Balland, E., Lacombe, A., Mazur, D., Carmeliet,
P., Bouret, S.G., Prevot, V. & Dehouck, B. (2013a) Tanycytic VEGF-A
boosts blood-hypothalamus barrier plasticity and access of metabolic
signals to the arcuate nucleus in response to fasting. Cell Metab., 17,
607–617.
Langlet, F., Mullier, A., Bouret, S.G., Prevot, V. & Dehouck, B. (2013b)
Tanycyte-like cells form a blood-cerebrospinal ﬂuid barrier in the
circumventricular organs of the mouse brain. J. Comp. Neurol., 521,
3389–3405.
Liberini, C., Boyle, C.N. & Lutz, T.A. (2013) Gene expression proﬁling of
single amylin-activated neuron in the rat area postrema 2013 Neuroscience
Meeting Planner. Society for Neuroscience, [Internet] San Diego, CA.
Lutz, T.A. (2012) Control of energy homeostasis by amylin. Cell. Mol. Life
Sci., 69, 1947–1965.
Lutz, T.A., Del Prete, E., Walzer, B. & Scharrer, E. (1996) The histaminer-
gic, but not the serotoninergic, system mediates amylin’s anorectic effect.
Peptides, 17, 1317–1322.
Lutz, T.A., Senn, M., Althaus, J., Del Prete, E., Ehrensperger, F. & Scharrer,
E. (1998) Lesion of the area postrema/nucleus of the solitary tract (AP/
NTS) attenuates the anorectic effects of amylin and calcitonin gene-related
peptide (CGRP) in rats. Peptides, 19, 309–317.
Lutz, T.A., Tschudy, S., Rushing, P.A. & Scharrer, E. (2000) Amylin recep-
tors mediate the anorectic action of salmon calcitonin (sCT). Peptides, 21,
233–238.
Lutz, T.A., Mollet, A., Rushing, P.A., Riediger, T. & Scharrer, E. (2001)
The anorectic effect of a chronic peripheral infusion of amylin is abolished
in area postrema/nucleus of the solitary tract (AP/NTS) lesioned rats. Int.
J. Obes. Relat. Metab. Disord., 25, 1005–1011.
Mack, C.M., Soares, C.J., Wilson, J.K., Athanacio, J.R., Turek, V.F., Trevas-
kis, J.L., Roth, J.D., Smith, P.A., Gedulin, B., Jodka, C.M., Roland, B.L.,
Adams, S.H., Lwin, A., Herich, J., Laugero, K.D., Vu, C., Pittner, R., Pat-
erniti, J.R. Jr., Hanley, M., Ghosh, S. & Parkes, D.G. (2010) Davalintide
(AC2307), a novel amylin-mimetic peptide: enhanced pharmacological
properties over native amylin to reduce food intake and body weight. Int.
J. Obesity, 34, 385–395.
Mietlicki-Baase, E.G., Rupprecht, L.E., Olivos, D.R., Zimmer, D.J., Alter,
M.D., Pierce, R.C., Schmidt, H.D. & Hayes, M.R. (2013) Amylin receptor
signaling in the ventral tegmental area is physiologically relevant for the
control of food intake. Neuropsychopharmacol., 38, 1685–1697.
Muff, R., Buhlmann, N., Fischer, J.A. & Born, W. (1999) An amylin recep-
tor is revealed following co-transfection of a calcitonin receptor with
receptor activity modifying proteins-1 or -3. Endocrinology, 140, 2924–
2927.
Ogawa, A., Harris, V., McCorkle, S.K., Unger, R.H. & Luskey, K.L. (1990)
Amylin secretion from the rat pancreas and its selective loss after strepto-
zotocin treatment. J. Clin. Invest., 85, 973–976.
Ormazabal, M.J., Goicoechea, C., Sanchez, E. & Martin, M.I. (2001) Salmon
calcitonin potentiates the analgesia induced by antidepressants. Pharmacol.
Biochem. Be., 68, 125–133.
Potes, C.S., Lutz, T.A. & Riediger, T. (2010a) Identiﬁcation of central pro-
jections from amylin-activated neurons to the lateral hypothalamus. Brain
Res., 1334, 31–44.
Potes, C.S., Turek, V.F., Cole, R.L., Vu, C., Roland, B.L., Roth, J.D., Riedi-
ger, T. & Lutz, T.A. (2010b) Noradrenergic neurons of the area postrema
mediate amylin’s hypophagic action. Am. J. Physiol.-Reg. I., 299, R623–
R631.
Prevot, V., Langlet, F. & Dehouck, B. (2013) Flipping the tanycyte switch:
how circulating signals gain direct access to the metabolic brain. Aging, 5,
332–334.
Punjabi, M., Arnold, M., Geary, N., Langhans, W. & Pacheco-Lopez, G.
(2011) Peripheral glucagon-like peptide-1 (GLP-1) and satiation. Physiol.
Behav., 105, 71–76.
Reidelberger, R.D., Kelsey, L. & Heimann, D. (2002) Effects of amylin-
related peptides on food intake, meal patterns, and gastric emptying in rats.
Am. J. Physiol.-Reg. I., 282, R1395–R1404.
Riediger, T., Schmid, H.A., Young, A.A. & Simon, E. (1999) Pharmacologi-
cal characterisation of amylin-related peptides activating subfornical organ
neurones. Brain Res., 837, 161–168.
© 2014 Federation of European Neuroscience Societies and John Wiley & Sons Ltd
European Journal of Neuroscience, 1–12
Anorectic effect of amylin and salmon calcitonin 11
Riediger, T., Schmid, H.A., Lutz, T.A. & Simon, E. (2002) Amylin and glu-
cose co-activate area postrema neurons of the rat. Neurosci. Lett., 328,
121–124.
Riediger, T., Zuend, D., Becskei, C. & Lutz, T.A. (2004) The anorectic hor-
mone amylin contributes to feeding-related changes of neuronal activity in
key structures of the gut-brain axis. Am. J. Physiol.-Reg. I., 286, R114–
R122.
Ritter, R.C. & Edwards, G.L. (1984) Area postrema lesions cause overcon-
sumption of palatable foods but not calories. Physiol. Behav., 32, 923–
927.
Rowland, N.E. & Richmond, R.M. (1999) Area postrema and the anorectic
actions of dexfenﬂuramine and amylin. Brain Res., 820, 86–91.
Rowland, N.E., Crews, E.C. & Gentry, R.M. (1997) Comparison of Fos
induced in rat brain by GLP-1 and amylin. Regul. Peptides, 71, 171–174.
Sexton, P.M., Paxinos, G., Kenney, M.A., Wookey, P.J. & Beaumont, K.
(1994) In vitro autoradiographic localization of amylin binding sites in rat
brain. Neuroscience, 62, 553–567.
Stornetta, R.L., Sevigny, C.P. & Guyenet, P.G. (2002) Vesicular glutamate
transporter DNPI/VGLUT2 mRNA is present in C1 and several other
groups of brainstem catecholaminergic neurons. J. Comp. Neurol., 444,
191–206.
Stricker, E.M., Curtis, K.S., Peacock, K.A. & Smith, J.C. (1997) Rats with
area postrema lesions have lengthy eating and drinking bouts when fed ad
libitum: implications for feedback inhibition of ingestive behavior. Behav.
Neurosci., 111, 623–632.
West, M.J., Slomianka, L. & Gundersen, H.J. (1991) Unbiased stereological
estimation of the total number of neurons in thesubdivisions of the rat hip-
pocampus using the optical fractionator. Anat. Rec., 231, 482–497.
Wimalawansa, S.J. (1997) Amylin, calcitonin gene-related peptide, calcitonin,
and adrenomedullin: a peptide superfamily. Crit. Rev. Neurobiol., 11,
167–239.
Yamamoto, H., Kishi, T., Lee, C.E., Choi, B.J., Fang, H., Hollenberg, A.N.,
Drucker, D.J. & Elmquist, J.K. (2003) Glucagon-like peptide-1-responsive
catecholamine neurons in the area postrema link peripheral glucagon-like
peptide-1 with central autonomic control sites. J. Neurosci., 23, 2939–
2946.
Zigman, J.M., Jones, J.E., Lee, C.E., Saper, C.B. & Elmquist, J.K. (2006)
Expression of ghrelin receptor mRNA in the rat and the mouse brain. J.
Comp. Neurol., 494, 528–548.
Zuger, D., Forster, K., Lutz, T.A. & Riediger, T. (2013) Amylin and GLP-1
target different populations of area postrema neurons that are both modu-
lated by nutrient stimuli. Physiol. Behav., 112–113, 61–69.
© 2014 Federation of European Neuroscience Societies and John Wiley & Sons Ltd
European Journal of Neuroscience, 1–12
12 F. E. Braegger et al.
Graphical Abstract
The contents of this page will be used as part of the graphical abstract of html only. It will not be published as part
of main article.
Responsive to amylin & sCT Non-responsive to amylin & sCT
NTS
PB
Vagal
input
NTS
PB
RVLM
Amylin
sCT
Amylin receptor
GLP-1 receptor
Glutamate
Undefined
Ghrelin receptor
Peptides & transmitters
Receptors
Catecholamine Fos+
Fos+
A B C D
?
In this study we show that lesions of the area postrema (AP) block feedback signals controlling meal size and affect the ability to compensate
for an energy deﬁcit following a fast. The AP is also required for both amylin and it’s analogue salmon calcitonin to produce the full inhibi-
tory effect on food intake and to induce Fos in the NTS. Like amylin, approximately 50% of sCT-activated neurons in the AP are noradrener-
gic, and VGLUT2 boutons abut roughly 95% of these cells.
